Pathovax, LLC is a Baltimore-based biotechnology company that specializes in the development of innovative vaccines. Their flagship product, HPV16 RG1-VLP, has recently received FDA clearance of its Investigational New Drug Application, marking a significant milestone in the quest for complete protection against the human papillomavirus.
With a focus on cutting-edge technology and scientific expertise, Pathovax is dedicated to advancing the field of vaccine research and development. Their breakthrough HPV vaccine offers promising potential in the prevention of HPV-related diseases, providing hope for improved public health outcomes.
Generated from the website